Lilly is also developing oral therapies for its gastroenterology pipeline.

Eli Lilly’s Alzheimer’s treatment, Kisunla (donanemab), scored a major win with approval in Australia, marking it as the ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...

Revenue grew 45% compared to Q1 of 2024. Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than $4 billion and now account for $7.5 ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist ...